Samsara Bio Capital, LLC Equillium, Inc. Transaction History

Samsara Bio Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.49 - $0.79 $301,615 - $486,277	-615,541 Closed	0 $0
Q1 2023 May 15, 2023	BUY	$0.56 - $1.24 $344,702 - $763,270	615,541 New	615,541 $449,000
Q4 2021 Feb 14, 2022	SELL	$3.77 - $6.99 $462,333 - $857,218	-122,635 Reduced 16.61%	615,541 $2.32 Million
Q2 2021 Aug 17, 2021	SELL	$5.11 - $7.64 $134,019 - $200,374	-26,227 Reduced 3.43%	738,176 $4.35 Million
Q1 2021 May 18, 2021	SELL	$5.03 - $10.5 $1.56 Million - $3.25 Million	-309,882 Reduced 28.85%	764,403 $5.47 Million
Q3 2020 Nov 16, 2020	BUY	$2.78 - $26.5 $2.99 Million - $28.5 Million	1,074,285 New	1,074,285 $6.2 Million

11.3M

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $21M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.